Panel Denies Motion For Belviq Weight Loss Drug Cancer MDL, Citing Too Few Cases
WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation (JPMDL) on Aug. 10 denied centralization of 20 federal lawsuits alleging that the withdrawn weight loss drug Belviq caused cancer, saying there...To view the full article, register now.
Already a subscriber? Click here to view full article